ok lets say 10% penetration rate for US market on diagnosed cohort = 370k sprits. Now obviously that is going to take considerable time - wot happen overnight.
500USDx 370k scripts x 12 months = $2.2B USD or $3.3M AUD
EBITDA at 30% = $1B AUD. Note 30% is reasonable for Biotech and even analyst report had much higher in proforma forecast >40% EBITDA percentage
note above does not take into account undiagnosed in US or Japna and Korea sales. Its massive potential
comparative is CSL - $13B revenue and return $3B EBITDA. CSL Share price is $300 with Market cap of $147B
BOT is market cap of >$700M. Ok not saying we are next CSL, but just trying to get perspective on the numbers that is being floated around and potential.
Please correct me if i am wrong and my maths is $hite or am missing something
BOT - Anything but charting, page-10474
-
- There are more pages in this discussion • 680 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.015(3.90%) |
Mkt cap ! $672.4M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $2.603M | 7.036M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 292539 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 24998 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |